Adverse Events reporting

Please report suspected side effects to the MHRA through the Yellow Card scheme, via the Yellow Card website www.mhra.gov.uk/yellowcard, the free Yellow Card app available in Apple App Store or Google Play Store. Alternatively, you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

Adverse Events reporting (continued)

By reporting side effects, you can help provide more information on the safety of this medicine.

Side effects should also be reported to Sanofi: Tel: 0800 0902314. email: uk-drugsafety@sanofi.com

INFORMATION FOR HEALTHCARE PROFESSIONALS

- CABLIVI (caplacizumab) is indicated for treatment of acquired thrombotic thrombocytopenic purpura in conjunction with plasma exchange and immunosuppression.
- Caplacizumab inhibits the interaction of von Willebrand Factor (vWF) with platelets.
- Caplacizumab may increase the risk of bleeding, including major bleeding.
- Cases of major bleeding, including potentially life-threatening and fatal bleeding, have been reported, mainly in patients using concomitant anti-platelet agents or anticoagulants.
- Caplacizumab should be used with caution in patients with underlying conditions associated with a bleeding risk.
- In case of significant bleeding requiring treatment, vWF/FVIII concentrate may be used to correct hemostasis.
- Caplacizumab treatment should be stopped 7 days before elective surgery.
- Please refer to the local label for full information.

sanofi

Cablivi caplacizumab

VV-PV-0664774 (v1.0)
Date of Preparation: September 2026
MHRA Approval Date: October 2026

PATIENT ALERT CARD

sanofi

Cablivi caplacizumab

Patient information

Name:

IN CASE OF EMERGENCY, PLEASE CONTACT:

Name:

Phone number:

Prescriber information

FOR MORE INFORMATION OR IN CASE OF EMERGENCY SITUATIONS, PLEASE CONTACT MY DOCTOR:

Name:

Phone number:

Treatment information

(To be completed by your physician)

On (date) _____ **this patient started taking CABLIVI (caplacizumab) for acquired Thrombotic Thrombocytopenic Purpura (aTTP).**

(to be completed by your physician or yourself if you self inject caplacizumab)

Actual end date of treatment _____

Information for patients

- Always keep this card with you while on caplacizumab treatment and for one week after your last dose.
- Taking caplacizumab may increase your risk of bleeding (including potentially life-threatening and fatal bleeding).
- Please contact your doctor immediately if you develop excessive bruising, bleeding or experience any unusual symptoms, such as headache, shortness of breath, tiredness, dizziness, lightheadedness or fainting during treatment.
- Present this card to your healthcare professional (e.g. physician, dentist or surgeon) before any medical treatment or intervention.
- Please read the caplacizumab Package Leaflet carefully.